The GLP-1 revolution is just the beginning. Several next-generation medications are in development that could offer even more weight loss, oral alternatives to injections, and new mechanisms of action. Here's what's on the horizon.
Oral semaglutide pill for weight loss
An oral tablet version of semaglutide (the same drug in Wegovy) launched in the United States in early 2026 for weight loss. This is significant because it offers the first non-injectable GLP-1 option for weight management. The pill uses a technology called SNAC to protect the peptide from stomach acid. As of April 2026, it's still being reviewed by the MHRA for UK approval.1
Retatrutide (Eli Lilly)
Retatrutide is a triple agonist — it targets GLP-1, GIP, and glucagon receptors (compared to tirzepatide's dual action). Phase 2 trials showed approximately 24% weight loss at the highest dose over 48 weeks, which extrapolates to potentially 25%+ over 72 weeks. Phase 3 trials are ongoing. If approved, it could surpass current medications in effectiveness.2
Orforglipron (Eli Lilly)
Orforglipron is an oral GLP-1 agonist — a daily pill rather than an injection. Phase 2 results showed approximately 14.7% weight loss over 36 weeks. Phase 3 trials are underway. If successful, it would offer an oral alternative to weekly injections with meaningful weight loss, potentially at a lower cost since pills are generally cheaper to manufacture than injectable pens.
What this means for patients
Competition in this space is driving innovation at an unprecedented pace. Within the next 2-5 years, patients may have access to oral GLP-1 pills (no more injections), triple-agonist medications with 25%+ weight loss, and more options meaning potentially lower prices through competition. For now, Mounjaro and Wegovy remain the leading options. For a comparison of what's currently available, see our comparison tool.